Form 4: Cardiff Oncology Director Renee P Tannenbaum Trades Shares

Director Renee P Tannenbaum of Cardiff Oncology, Inc. engaged in a transaction involving the purchase and disposal of company stock on December 12, 2024.

Summary

• Renee P Tannenbaum, a director at Cardiff Oncology, Inc., filed a Form 4 indicating changes in beneficial ownership.
• On December 12, 2024, Tannenbaum acquired 10,000 shares of common stock at a price of $3.4224 per share.
• On the same day, Tannenbaum disposed of 20,000 shares of common stock.
• The filing indicates that the transactions were made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The document is a routine filing of insider trading activity. It does not indicate any positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider trading.
• The transactions are not unusual for directors who may have pre-arranged trading plans.

Stakeholder Impact

• The transactions may have a minor impact on the stock price, but are likely to be viewed as routine insider trading activity.

Key Dates

Keywords

Cardiff Oncology, CRDF, Renee P Tannenbaum, Form 4, insider trading, beneficial ownership, stock transaction, Rule 10b5-1